Abstract: In one embodiment, the present disclosure provides an engineered cell having a first chimeric antigen receptor polypeptide including a first antigen recognition domain, a first signal peptide, a first hinge region, a first transmembrane domain, a first costimulatory domain, and a first signaling domain; and a second chimeric antigen receptor polypeptide including a second antigen recognition domain, a second signal peptide, a second hinge region, a second transmembrane domain, a second co-stimulatory domain, and a second signaling domain; wherein the first antigen recognition domain is different than the second antigen recognition domain.
Type:
Grant
Filed:
October 12, 2018
Date of Patent:
February 20, 2024
Assignee:
ICell Gene Therapeutics Inc.
Inventors:
Yupo Ma, Kevin Pinz, Xun Jiang, Masayuki Wada, Kevin Chen
Abstract: The present disclosure provides chimeric antigen receptors, compostions, and methods thereof. In one embodiment the present disclosure provides a method of treating autoimmune diseases, asthma, and preventing or mediating organ rejection in a subject.
Type:
Grant
Filed:
June 21, 2017
Date of Patent:
November 21, 2023
Assignee:
iCell Gene Therapeutics Inc.
Inventors:
Yupo Ma, Kevin Pinz, Xun Jiang, Masayuki Wada, Kevin Chen
Abstract: The present invention relates to compositions and methods relating to chimeric antigen receptor (CAR) polypeptides and methods relating thereto. In one embodiment, the present invention relates to engineered cells having chimeric antigen receptor polypeptides directed to at least two targets. In another embodiment, the present invention relates to engineered cells having chimeric antigen receptor polypeptides and an enhancer moiety.
Type:
Grant
Filed:
June 24, 2016
Date of Patent:
May 23, 2023
Assignee:
iCell Gene Therapeutics Inc.
Inventors:
Yupo Ma, Kevin Pinz, Xun Jiang, Masayuki Wada, Kevin Chen